Brian CorderyFew would dispute that the Actavis v Eli Lilly decision from the Supreme Court in July 2017 represented – for better or for worse – a major change to the scope of protection of patents in the UK. [read post]

Prelude to Litigation Phenylpropanolamine (PPA) was a widely used direct α-adrenergic agonist used as a medication to control cold symptoms and to suppress appetite for weight loss.[1] In 1972, an over-the-counter (OTC) Advisory Review Panel considered the safety and efficacy of PPA-containing nasal decongestant medications, leading, in 1976, to a recommendation that the agency label these medications as “generally recognized as safe and effective. [read post]